Saturday, May 30, 2020 7:52:09 AM
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOUGLAS RICHARD
Director Mar 16 Buy 2.75 40,000 110,000 125,000 Mar 17 04:38 PM
Brady Todd C
President and CEO Dec 16 Buy 5.10 20,000 101,908 652,216 Dec 18 07:35 AM
Brady Todd C
President and CEO Sep 30 Buy 5.68 8,710 49,483 632,216 Oct 02 07:36 AM
Brady Todd C
President and CEO Sep 23 Buy 5.81 8,680 50,433 623,506 Sep 25 07:40 AM
Brady Todd C
President and CEO Sep 18 Buy 5.91 14,288 84,465 614,826 Sep 20 07:37 AM
Bronstein Ben
Director Sep 17 Buy 5.85 1,700 9,945 18,644 Sep 19 04:23 PM
Brady Todd C
President and CEO Sep 16 Buy 6.03 3,000 18,090 591,991 Sep 17 07:35 AM
DOUGLAS RICHARD
Director Sep 13 Buy 6.00 5,000 30,000 85,000 Sep 17 07:36 AM
Brady Todd C
President and CEO Sep 13 Buy 5.79 10,000 57,900 588,991 Sep 17 07:35 AM
DOUGLAS RICHARD
Director Sep 12 Buy 6.03 10,000 60,276 80,000 Sep 13 07:54 AM
JOYCE MARTIN JOSEPH
Director Sep 12 Buy 5.86 1,700 9,964 19,644 Sep 16 04:15 PM
DOUGLAS RICHARD
Director Sep 11 Buy 5.75 10,000 57,529 70,000 Sep 13 07:54 AM
DOUGLAS RICHARD
Director Sep 10 Buy 5.09 10,000 50,857 60,000 Sep 11 04:05 PM
Brady Todd C
President and CEO Sep 10 Buy 5.39 10,000 53,937 578,991 Sep 11 04:05 PM
DOUGLAS RICHARD
Director Sep 09 Buy 4.91 10,000 49,106 50,000 Sep 11 04:05 PM
Brady Todd C
President and CEO Sep 09 Buy 4.89 10,000 48,887 568,991 Sep 11 04:05 PM
Clark David J
Chief Medical Officer Sep 06 Buy 5.06 5,000 25,311 17,878 Sep 10 05:01 PM
Reed Joshua
Chief Financial Officer Sep 05 Buy 4.71 3,200 15,072 35,774 Sep 09 04:38 PM
McMullin David
Chief Commerical Officer Sep 05 Buy 4.68 4,329 20,260 6,148 Sep 09 04:37 PM
Shs Outstand 29.21M
Shs Float 25.52M
Market Cap 145.53M
Stock price $10 Market Cap 10 x 29.21 = 292.1 M
Stock price $20 Market Cap 20 x 29.21 = 584.2 M
Stock price $40 Market Cap 40 x 29.21 = 1,168.4 M
The close of $4.92 now has the support based on the 200 DMA of $4.75 and 40 week MA of $4.79. Volume is worth noting as well as the LACK of SHORT INTEREST at 1.9%
Looking at Market Cap, SRNE has 1 billion MC for example. INO and NVAX are 2-3 B. I think ALDX is significantly undervalued even at $20 based on Market Cap.
Data from:
https://finviz.com/quote.ashx?t=aldx&ty=c&ta=1&p=d
https://stockcharts.com/freecharts/gallery.html?aldx
Recent ALDX News
- Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting • Business Wire • 10/31/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/22/2024 12:22:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2024 11:01:12 AM
- Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease • Business Wire • 10/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 08:10:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:15:22 PM
- Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 09/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 01:02:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:24:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 10:07:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 09:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:06:48 AM
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap • Business Wire • 08/08/2024 11:00:00 AM
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap • Business Wire • 08/07/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/01/2024 09:01:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:11:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:03:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:01:40 AM
- Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 11:01:34 AM
- Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease • Business Wire • 06/13/2024 11:00:00 AM
- Aldeyra Therapeutics to Host Investor Roundtable Q&A • Business Wire • 06/12/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:07:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 08:12:36 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM